Exelixis | EXEL - Aktuelle Verpflichtungen

Aktienkurs
44.94
Täglich Wechseln
-1.11 -2.41%
Monatlich
5.04%
Jährlich
20.06%
Q2 Prognose
43.98




Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Akebia Therapeutics USD 162.94M 29.56M 2025-12
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Bayer EUR 32.58B 3.63B 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Cytokinetics USD 202.45M 60.31M 2025-12
Eisai JPY 387.67B 9.42B 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Genmab DKK 1.43B 686M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
MacroGenics USD 43.11M 1.36M 2025-12
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 28.35B 9.32B 2025-12
Takeda JPY 2.61T 470.53B 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Xencor USD 95.91M 9.42M 2025-12